Taysha Gene Therapies (NASDAQ:TSHA) Rating Reiterated by JMP Securities

Taysha Gene Therapies (NASDAQ:TSHAGet Free Report)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a research note issued to investors on Thursday, Benzinga reports. They currently have a $5.00 target price on the stock. JMP Securities’ price target would indicate a potential upside of 77.30% from the company’s current price.

TSHA has been the topic of several other reports. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday. Canaccord Genuity Group restated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Piper Sandler initiated coverage on Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an “overweight” rating and a $9.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Monday. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of “Buy” and a consensus price target of $7.00.

Get Our Latest Analysis on TSHA

Taysha Gene Therapies Price Performance

TSHA stock traded down $0.15 during trading on Thursday, hitting $2.82. The company had a trading volume of 1,308,744 shares, compared to its average volume of 2,456,221. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. The business has a 50 day moving average of $3.00 and a 200 day moving average of $2.38. Taysha Gene Therapies has a fifty-two week low of $0.50 and a fifty-two week high of $4.32. The firm has a market capitalization of $527.40 million, a price-to-earnings ratio of -5.75 and a beta of 0.50.

Taysha Gene Therapies (NASDAQ:TSHAGet Free Report) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The firm had revenue of $3.41 million for the quarter, compared to analysts’ expectations of $3.70 million. During the same period in the previous year, the business earned ($0.28) earnings per share. As a group, research analysts predict that Taysha Gene Therapies will post -0.43 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Artal Group S.A. lifted its holdings in shares of Taysha Gene Therapies by 0.7% during the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after buying an additional 24,444 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Taysha Gene Therapies by 328.2% in the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after purchasing an additional 14,294,445 shares in the last quarter. StemPoint Capital LP acquired a new position in shares of Taysha Gene Therapies in the first quarter valued at $3,122,000. Quantum Private Wealth LLC raised its stake in shares of Taysha Gene Therapies by 9.2% in the first quarter. Quantum Private Wealth LLC now owns 698,520 shares of the company’s stock valued at $2,005,000 after purchasing an additional 59,000 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Taysha Gene Therapies by 66.1% in the first quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after purchasing an additional 14,286 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.

Further Reading

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.